Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study intends to evaluate the feasibility and treatment efficacy of adding an antibody
blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven
efficacy developed at New York University.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
Bristol-Myers Squibb Eli Lilly and Company ImClone LLC